Literature DB >> 86546

Interaction of digitalis and spironolactone with human sex steroid receptors.

S M Rifka, J C Pita, R A Vigersky, Y A Wilson, D L Loriaux.   

Abstract

Spironolactone and digitoxin have previously been shown to interact with cytosol androgen and estrogen receptors, respectively, in the rat. The interaction of digitoxin with human uterine cytosol estrogen binding protein and spironolactone with human prostate and newborn prepuce cytosol dihydrotestosterone (DHT) binding protein has been analyzed in this study. Specific estradiol binding was found only in premenopausal uteri. The dissociation constant for estradiol binding was 0.6--2.3 X 10(-9) M (n - 12). Digitoxin in concentrations varying between 0.5--2.0 X 10(-6) M inhibited specific estradiol binding with a Ki of 2.0--7.3 X 10(-7) M (n = 9). The dissociation constants for DHT and the human androgen cytosol binding protein in prostate and newborn prepuce were 0.27--3.0 X 10(-8) M (n = 12) and 0.6--2.0 X 10(-8) M (n = 5), respectively. Spironolactone at concentrations of 0.3--2.0 X 10(-6) M competitively inhibited this binding with an affinity about one order of magnitude less than that of DHT. Digitoxin and spironolactone did not displace estradiol and DHT, respectively, from testosterone-estrogen binding globulin in male or female plasma. The interaction of digitoxin with the human uterus estrogen binding protein and spironolactone with the human prostate and prepuce androgen binding protein is similar to our previous observations in the rat, and may explain the weak estrogenic effects of digitoxin and spironolactone in man.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 86546     DOI: 10.1210/jcem-46-2-338

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

Review 1.  Chemistry and structural biology of androgen receptor.

Authors:  Wenqing Gao; Casey E Bohl; James T Dalton
Journal:  Chem Rev       Date:  2005-09       Impact factor: 60.622

Review 2.  Gynaecomastia--pathophysiology, diagnosis and treatment.

Authors:  Harmeet S Narula; Harold E Carlson
Journal:  Nat Rev Endocrinol       Date:  2014-08-12       Impact factor: 43.330

Review 3.  Hirsutism and the effectiveness of spironolactone in its management.

Authors:  G R McMullen; A J Van Herle
Journal:  J Endocrinol Invest       Date:  1993-12       Impact factor: 4.256

Review 4.  Diuretics. Clinical pharmacology and therapeutic use (Part II).

Authors:  A Lant
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

5.  Use of cardiac glycosides and risk of glioma.

Authors:  Corinna Seliger; Christoph R Meier; Susan S Jick; Martin Uhl; Ulrich Bogdahn; Peter Hau; M F Leitzmann
Journal:  J Neurooncol       Date:  2015-12-31       Impact factor: 4.130

6.  Effect of spironolactone and potassium canrenoate on cytosolic and nuclear androgen and estrogen receptors of rat liver.

Authors:  A Francavilla; A Di Leo; P K Eagon; L Polimeno; F Guglielmi; G Fanizza; M Barone; T E Starzl
Journal:  Gastroenterology       Date:  1987-10       Impact factor: 22.682

7.  [No effect of digitalis on sex and adrenal hormones in healthy subjects and in patients with congestive heart failure].

Authors:  H K Kley; H Abendroth; R Hehrmann; A Müller; E Keck; H Schneitler; H Elsässer; H L Krüskemper
Journal:  Klin Wochenschr       Date:  1984-01-16

8.  Digoxin use and risk of invasive breast cancer: evidence from the Nurses' Health Study and meta-analysis.

Authors:  Thomas P Ahern; Rulla M Tamimi; Bernard A Rosner; Susan E Hankinson
Journal:  Breast Cancer Res Treat       Date:  2014-02-28       Impact factor: 4.872

Review 9.  Effects of antihypertensive drugs on endocrine function.

Authors:  E P Brass
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

10.  The interaction of canrenone with oestrogen and progesterone receptors in human uterine cytosol.

Authors:  M D Fernandez; G D Carter; T N Palmer
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.